Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
作者： Wei He
DOI:
关键词:
摘要: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases autoimmune inflammatory diseases). The comprise the combined use of inhibitors BTK, mTOR kinase, Bcl-2 or their signaling pathways, immunomodulatory drugs. Also described pharmaceutical compositions kits comprising these inhibitors.
lens.org 参考文章(31)
David Michael Goldstein, Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases. ,(2013)
Joachim Fensterle, Ivaylo Nikolov Gentschev, Werner Goebel, Ulf R. Rapp, Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof ,(2007)
Scott A. Ezell, Michele Mayo, Teeru Bihani, Suprawee Tepsuporn, Suping Wang, Melissa Passino, Shaun E. Grosskurth, Mike Collins, Julie Parmentier, Corinne Reimer, Kate F. Byth, Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma Oncotarget. ,vol. 5, pp. 4990- 5001 ,(2014) , 10.18632/ONCOTARGET.2071
Erik Verner, Tim Owens, Pyrazolopyrimidine compounds as kinase inhibitors ,(2013)
Paul Shinn, Rajarshi Guha, Marc Ferrer, Craig Thomas, Thomas A. Waldmann, Louis M. Staudt, Yibin Yang, Arthur L. Shaffer, N.C. Tolga Emre, Michele Ceribelli, Meili Zhang, George Wright, Wenming Xiao, John Powell, John Platig, Holger Kohlhammer, Ryan M. Young, Hong Zhao, Yandan Yang, Weihong Xu, Joseph J. Buggy, Sriram Balasubramanian, Lesley A. Mathews, Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma Cancer Cell. ,vol. 21, pp. 723- 737 ,(2012) , 10.1016/J.CCR.2012.05.024
Qing Shi, Andrew Tebben, Alaric J. Dyckman, Hedy Li, Chunjian Liu, James Lin, Steve Spergel, James R. Burke, Kim W. McIntyre, Gilbert C. Olini, Joann Strnad, Neha Surti, Jodi K. Muckelbauer, Chiehying Chang, Yongmi An, Lin Cheng, Qian Ruan, Katerina Leftheris, Percy H. Carter, Joseph Tino, George V. De Lucca, Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases Bioorganic & Medicinal Chemistry Letters. ,vol. 24, pp. 2206- 2211 ,(2014) , 10.1016/J.BMCL.2014.02.075
Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson, Diffuse large B-cell lymphoma—treatment approaches in the molecular era Nature Reviews Clinical Oncology. ,vol. 11, pp. 12- 23 ,(2014) , 10.1038/NRCLINONC.2013.197
L. Vargas, A. Hamasy, B. F. Nore, C. I. E. Smith, Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scandinavian Journal of Immunology. ,vol. 78, pp. 130- 139 ,(2013) , 10.1111/SJI.12069
Eleonora Marostica, Juthamas Sukbuntherng, David Loury, Jan De Jong, Xavier Woot De Trixhe, An Vermeulen, Giuseppe De Nicolao, Susan O’Brien, John C Byrd, Ranjana Advani, Jesse McGreivy, Italo Poggesi, None, Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemotherapy and Pharmacology. ,vol. 75, pp. 111- 121 ,(2015) , 10.1007/S00280-014-2617-3
Kathrin Wanner, Susanne Hipp, Madlene Oelsner, Ingo Ringshausen, Christian Bogner, Christian Peschel, Thomas Decker, Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab British Journal of Haematology. ,vol. 134, pp. 475- 484 ,(2006) , 10.1111/J.1365-2141.2006.06210.X